Greenwich LifeSciences sells $2.5 million of stock to CEO Snehal Patel
On June 13, 2024, Greenwich LifeSciences agreed to sell 174,825 common shares to its CEO, Snehal Patel, in a private placement for approximately $2.5 million in gross proceeds before offering expenses. The shares are restricted, carry no registration rights, and are expected to close on June 18, 2024. The company plans to use the net proceeds for clinical development and working capital, and the sale adds new shares to the outstanding count.
Key points
- 174,825 shares of common stock priced at $14.30 per share, the Nasdaq official closing price on June 12, 2024
- Gross proceeds of approximately $2.5 million before offering expenses
- Closing expected June 18, 2024, subject to customary closing conditions
- Shares are restricted securities with no registration rights, sold under Section 4(a)(2) and/or Rule 506
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 17, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.